<DOC>
	<DOCNO>NCT00052923</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop tumor cell divide stop grow die . Combining chemotherapy stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . Monoclonal antibody , rituximab , locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know whether stem cell transplantation effective without rituximab treat relapse progressive B-cell diffuse large cell lymphoma . PURPOSE : Randomized phase III trial compare effectiveness stem cell transplantation without rituximab treat patient relapsed progressive B-cell diffuse large cell lymphoma .</brief_summary>
	<brief_title>Stem Cell Transplantation With Without Rituximab Treating Patients With Relapsed Progressive B-Cell Diffuse Large Cell Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Compare disease-free survival patient relapse progressive B-cell diffuse large cell lymphoma undergo stem cell transplantation without post-transplant rituximab . - Evaluate effect rituximab , administer post-transplant , procedure-related mortality patient . - Determine potential infectious complication addition drug autologous stem cell transplantation patient . - Compare overall survival patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord relapse ( relapsed 6 month either initial complete remission [ CR ] CR positive positron emission tomography MRI [ gallium ] v fail achieve initial CR relapse within 6 month either initial CR CR positive PET MRI [ gallium ] ) prior rituximab ( yes v ) . Stem cell mobilization - Patients receive rituximab IV 4-8 hour day 1 5 . Patients also receive cyclophosphamide IV 2 hour day 8 filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 9 continue last day apheresis . Stem cell collect 1-3 day . Preparative regimen - Regimen A ( patient receive prior radiotherapy ≥ 61 year age ) : Patients receive carmustine IV 2 hour day -6 , etoposide IV 4 hour day -4 , cyclophosphamide IV 2 hour day -2 . - Regimen B ( patient ) : Patients undergo total body irradiation twice daily day -8 -5 . Patients receive etoposide IV 4 hour day -4 cyclophosphamide IV 2 hour day -2 . Stem cell reinfused day 0 . Patients randomize one two post-transplant treatment arm . Post-transplant treatment - Arm I ( rituximab ) : Patients receive G-CSF SC begin day 6 continue blood count recover . Patients receive rituximab IV 4-8 hour every 7 day 4 dos , start day 45 post-transplant . Course rituximab repeat begin day 180 post-transplant . - Arm II ( rituximab ) : Patients receive G-CSF arm I . Patients follow 10 year . PROJECTED ACCRUAL : A total 427 patient accrue study within 3.5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis diffuse large cell lymphoma meeting follow criterion : Bcell type expression CD20 either diagnosis relapse Relapse achieve initial complete remission ( CR ) failure achieve initial CR ( residual radiographic abnormality primary therapy allow abnormality also positive positron emission tomography MRI [ gallium ] ) No newly diagnose disease No progressive stable disease recent salvage therapy PATIENT CHARACTERISTICS : Age 18 70 Performance status ECOG 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,000/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic Bilirubin ≤ 2.0 mg/dL AST ALT &lt; 3 time upper limit normal Renal Creatinine ≤ 2.0 mg/dL OR Creatinine clearance ≥ 40 mL/min Cardiovascular Cardiac ejection fraction ≥ 40 % Pulmonary DLCO ≥ 60 % predict Other No malignancy within past 2 year except basal cell skin cancer carcinoma situ cervix No active infection require oral IV antibiotic HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy See Chemotherapy No 3 prior immunotherapy regimen Chemotherapy No 3 prior chemotherapy regimen Addition radiation monoclonal antibody chemotherapy consider one treatment regimen addition part initial treatment plan Addition therapy due lack response poor response would consider additional treatment regimen whether give frontline salvage set Endocrine therapy Not specify Radiotherapy See Chemotherapy No 3 prior radiotherapy regimens No prior radioimmunotherapy Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2006</verification_date>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
</DOC>